Representing diverse communities within our clinical trials is essential for understanding and treating disease—the more diverse the participants, the more our researchers can learn about the different ways in which people respond to treatments.
Because studies have shown that minorities and people from historically marginalized groups in the U.S. are less likely to be included in clinical research, we’ve made it a priority to remove participation barriers and increase racial and ethnic diversity in our clinical trials.
To advance this mission, a sub-committee of our Inclusion Team focused on clinical trials created a new iDIRECT (Incyte Diversity, Inclusion, Representation and Equity in Clinical Trials) team dedicated to promoting diversity in clinical trials. The iDIRECT team identified strengths and opportunities for improving diversity in our current clinical trials and suggested strategies to enhance diverse participation in future trials.
These insights informed our new Clinical Trial Diversity Roadmap. Guided by the Roadmap, we’ve established a standard approach to determining diversity enrollment goals, launched a dashboard detailing diversity enrollment metrics for U.S. clinical studies, and leveraged real world evidence to identify sites that can enroll diverse patients and invite them to participate in our studies.
